Forton, Daniel

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 497

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 287

Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement

Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology

Hepatitis C virus researchTryptophan and brain disorders

Cited by 225

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Cordell, H. J., Fryett, J. J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., Kawashima, M., Nishida, N., Khor, S.-S., Gervais, O., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 182

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 155

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107

Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome

Russell, A., Hepgul, N., Nikkheslat, N., Borsini, A., Zajkowska, Z., Moll, N., Forton, D., Agarwal, K., Chalder, T., Mondelli, V., et al. (2019) · Psychoneuroendocrinology

Fibromyalgia and Chronic Fatigue Syndrome ResearchLong-Term Effects of COVID-19

Cited by 83

Transcriptomics in interferon-α-treated patients identifies inflammation-, neuroplasticity- and oxidative stress-related signatures as predictors and correlates of depression

Hepgul, N., Cattaneo, A., Agarwal, K., Baraldi, S., Borsini, A., Bufalino, C., Forton, D. M., Mondelli, V., Nikkheslat, N., Lopizzo, N., et al. (2016) · Neuropsychopharmacology

Tryptophan and brain disordersTreatment of Major Depression

Cited by 62

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Asselta, R., Paraboschi, E. M., Gerussi, A., Cordell, H. J., Mells, G. F., Sandford, R. N., Jones, D. E., Nakamura, M., Ueno, K., Hitomi, Y., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 55